Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37519
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSaposnik, G.-
dc.contributor.authorAndhavarapu, S.-
dc.contributor.authorFernandez, O.-
dc.contributor.authorKim, H. J.-
dc.contributor.authorWiendl, H.-
dc.contributor.authorFoss, M.-
dc.contributor.authorZuo, F.-
dc.contributor.authorHavrdova, E. K.-
dc.contributor.authorCelius, E.-
dc.contributor.authorCaceres, F.-
dc.contributor.authorMagyari, M.-
dc.contributor.authorBermel, R.-
dc.contributor.authorCosta, A.-
dc.contributor.authorTerzaghi, M.-
dc.contributor.authorKalincik, T.-
dc.contributor.authorPOPESCU, Veronica-
dc.contributor.authorAmato, M. P.-
dc.contributor.authorMontalban, X.-
dc.contributor.authorOh, J.-
dc.date.accessioned2022-06-14T08:20:26Z-
dc.date.available2022-06-14T08:20:26Z-
dc.date.issued2022-
dc.date.submitted2022-06-01T13:58:51Z-
dc.identifier.citationMultiple Sclerosis and Related Disorders, 58 , p. 103404 (Art N° 103404)-
dc.identifier.urihttp://hdl.handle.net/1942/37519-
dc.description.abstractBackground: Previous studies in multiple sclerosis (MS) showed that therapeutic inertia (TI) affects 60-90% of neurologists and up to 25% of daily treatment decisions. The objective of this study was to determine the most common factors and attribute levels associated with decisions to treatment escalation in an international study in MS care. Methods: 300 neurologists with MS expertise from 20 countries were invited to participate. Participants were presented with 12 pairs of simulated MS patient profiles described by 13 clinically relevant factors. We used disaggregated discrete choice experiments to estimate the weight of factors and attributes affecting physicians' decisions when considering treatment selection. Participants were asked to select the ideal candidate for treat-ment escalation from modest to higher-efficacy therapies. Results: Overall, 229 neurologists completed the study (completion rate: 76.3%). The top 3 weighted factors associated with treatment escalation were: previous relapses (20%), baseline expanded disability status scale [EDSS] (18%), and MRI activity (13%). Patient demographics and desire for pregnancy had a modest influence (<= 3%). We observed differences in the weight of factors associated with treatment escalation between MS specialists and non-MS specialists. Conclusions: Our results provide critical information on factors influencing neurologists' treatment decisions and should be applied to continuing medical education strategies.-
dc.description.sponsorshipThe authors are most grateful to all colleague neurologists participating in the study and to Prof. Kevin Thorpe for suggestions regarding the statistical analysis. We appreciate the support from the Department of Economics at the University of Zurich by facilitating access to the Qualtrics platform. Drs. Saposnik and Zuo had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.-
dc.language.isoen-
dc.publisherELSEVIER SCI LTD-
dc.rights2021 Elsevier B.V. All rights reserved.-
dc.subject.otherMultiple sclerosis-
dc.subject.otherDisease-modifying therapy-
dc.subject.otherTherapeutic inertia-
dc.subject.otherNeuroeconomics-
dc.subject.otherDecision making-
dc.subject.otherRisk-
dc.titleFactors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study-
dc.typeJournal Contribution-
dc.identifier.spage103404-
dc.identifier.volume58-
local.format.pages7-
local.bibliographicCitation.jcatA1-
dc.description.notesSaposnik, G (corresponding author), Univ Toronto, Div Neurol, Clin Outcomes & Decis Neurosci Unit, St Michaels Hosp,Dept Med, 55 Queen St E, Toronto, ON M5C 1R6, Canada.-
dc.description.notesgustavo.saposnik@unityhealth.to-
local.publisher.placeTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr103404-
dc.identifier.doi10.1016/j.msard.2021.103404-
dc.identifier.pmid35216786-
dc.identifier.isiWOS:000793561600014-
dc.contributor.orcidMontalban, Xavier/0000-0002-0098-9918; Popescu,-
dc.contributor.orcidVeronica/0000-0002-7156-5442-
local.provider.typewosris-
local.description.affiliation[Saposnik, G.; Oh, J.] Univ Toronto, Dept Med, Div Neurol, St Michaels Hosp, 55 Queen St E, Toronto, ON M5C 1R6, Canada.-
local.description.affiliation[Saposnik, G.] NeuroEconSolutions, Toronto, ON, Canada.-
local.description.affiliation[Saposnik, G.; Andhavarapu, S.; Terzaghi, M.] Univ Toronto, Clin Outcomes & Decis Neurosci Unit, St Michaels Hosp, Toronto, ON, Canada.-
local.description.affiliation[Saposnik, G.; Zuo, F.; Terzaghi, M.; Oh, J.] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada.-
local.description.affiliation[Fernandez, O.] Univ Malaga, Reg Univ Hosp Malaga, Inst Biomed Res Malaga, Dept Pharmacol,Fac Med, Malaga, Spain.-
local.description.affiliation[Kim, H. J.] Natl Canc Ctr, Dept Neurol, Res Inst & Hosp, Goyang, South Korea.-
local.description.affiliation[Wiendl, H.] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany.-
local.description.affiliation[Foss, M.] Bootstrap Analyt, Calgary, AB, Canada.-
local.description.affiliation[Havrdova, E. K.] Charles Univ Prague, Med Fac 1, Ctr Clin Neurosci, Dept Neurol, Prague, Czech Republic.-
local.description.affiliation[Celius, E.] Univ Oslo, Oslo Univ Hosp, Inst Clin Med, Dept Neurol, Oslo, Norway.-
local.description.affiliation[Caceres, F.] Inst Restorat Neurosci, Buenos Aires, DF, Argentina.-
local.description.affiliation[Magyari, M.] Univ Hosp Rigshosp, Danish Multiple Sclerosis Ctr, Copenhagen, Denmark.-
local.description.affiliation[Bermel, R.] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH 44106 USA.-
local.description.affiliation[Costa, A.] Univ Porto, Ctr Hosp Univ Sao Joao, Neurol Dept, Fac Med, Porto, Portugal.-
local.description.affiliation[Kalincik, T.] Univ Melbourne, Royal Melbourne Hosp Core Unit, MS Ctr, Dept Med, Melborne, Australia.-
local.description.affiliation[Popescu, V] Noorderhart Hosp, Univ MS Ctr, Pelt, Belgium.-
local.description.affiliation[Popescu, V] Hasselt Univ, Hasselt, Belgium.-
local.description.affiliation[Amato, M. P.] Univ Florence, IRCCS Fdn Don Carlo Gnocchi, Dept Neurofarba, Florence, Italy.-
local.description.affiliation[Montalban, X.] Univ Autonoma Barcelona, Hosp Vall dHebron, Ctr Esclerosi Mutiple Catalunya, Dept Neurol, Barcelona, Spain.-
local.uhasselt.internationalyes-
item.fullcitationSaposnik, G.; Andhavarapu, S.; Fernandez, O.; Kim, H. J.; Wiendl, H.; Foss, M.; Zuo, F.; Havrdova, E. K.; Celius, E.; Caceres, F.; Magyari, M.; Bermel, R.; Costa, A.; Terzaghi, M.; Kalincik, T.; POPESCU, Veronica; Amato, M. P.; Montalban, X. & Oh, J. (2022) Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study. In: Multiple Sclerosis and Related Disorders, 58 , p. 103404 (Art N° 103404).-
item.validationecoom 2023-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.contributorSaposnik, G.-
item.contributorAndhavarapu, S.-
item.contributorFernandez, O.-
item.contributorKim, H. J.-
item.contributorWiendl, H.-
item.contributorFoss, M.-
item.contributorZuo, F.-
item.contributorHavrdova, E. K.-
item.contributorCelius, E.-
item.contributorCaceres, F.-
item.contributorMagyari, M.-
item.contributorBermel, R.-
item.contributorCosta, A.-
item.contributorTerzaghi, M.-
item.contributorKalincik, T.-
item.contributorPOPESCU, Veronica-
item.contributorAmato, M. P.-
item.contributorMontalban, X.-
item.contributorOh, J.-
crisitem.journal.issn2211-0348-
crisitem.journal.eissn2211-0356-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.